[HTML][HTML] Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review
TS Monga, M Ekong, K Patrick, TGB Boyena… - Cureus, 2024 - ncbi.nlm.nih.gov
Cardiac amyloidosis (CA) involves the abnormal deposition and accumulation of amyloid
proteins in the heart muscle. A hallmark of disease progression is declining heart function …
proteins in the heart muscle. A hallmark of disease progression is declining heart function …
Nursing teleconsultation for the outpatient management of patients with cardiovascular disease during COVID-19 pandemic
V Russo, R Cassini, V Caso, C Donno… - International journal of …, 2021 - mdpi.com
Introduction: During the COVID-19 outbreak, non-urgent clinic visits or cardiac interventional
procedures were postponed to a later date, and the implementation of telemedicine has …
procedures were postponed to a later date, and the implementation of telemedicine has …
Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review
M Nabiee, S Dashti-Khavidaki… - Expert Review of Clinical …, 2020 - Taylor & Francis
ABSTRACT Introduction Direct oral anticoagulants (DOACs) are widely prescribed
nowadays. Available DOACs are renally eliminated to some extent and need dose …
nowadays. Available DOACs are renally eliminated to some extent and need dose …
Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment
V Perera, G Abelian, D Li, Z Wang, L Zhang… - Clinical …, 2022 - Springer
Objective The aim of this study was to assess the effect of moderate or severe renal
impairment on the pharmacokinetic (PK) properties of milvexian. Methods This open-label …
impairment on the pharmacokinetic (PK) properties of milvexian. Methods This open-label …
Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
Atrial fibrillation is a highly prevalent cardiac arrhythmia. It is associated with numerous co
mobilities. Approximately 30% of diabetic patients have atrial fibrillation and 15% of atrial …
mobilities. Approximately 30% of diabetic patients have atrial fibrillation and 15% of atrial …
[PDF][PDF] Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease
MI Chashkina, DA Andreev, NL Kozlovskaya… - …, 2020 - pdfs.semanticscholar.org
Aim To evaluate safety of using rivaroxaban in patients with stage 4 chronic kidney disease
(CKD) or transient, stable decline of glomerular filtration rate (GFR) to 15–29 ml/min/1.73 m2 …
(CKD) or transient, stable decline of glomerular filtration rate (GFR) to 15–29 ml/min/1.73 m2 …
[HTML][HTML] Prevalence of advanced chronic kidney disease in patients with nonvalvular atrial fibrillation hospitalized in cardiology departments
MI Chashkina, NL Kozlovskaya, DA Andreev… - Kardiologiia, 2020 - lib.ossn.ru
Objective. To estimate the prevalence of chronic kidney disease (CKD) 3b–5 stages and the
newly diagnosed sustained reduction in glomerular filtration rate (GFR)< 30 ml/min/1.73 m2 …
newly diagnosed sustained reduction in glomerular filtration rate (GFR)< 30 ml/min/1.73 m2 …
Диагностика и лечение фибрилляции предсердий
СП Голицын, ЕП Панченко, ЕС Кропачева… - Евразийский …, 2019 - cyberleninka.ru
В настоящем документе представлены актуальные на сегодняшний день
рекомендации по диагностике и лечению фибрилляции предсердий (ФП) …
рекомендации по диагностике и лечению фибрилляции предсердий (ФП) …
Temporal trends and in‐hospital complications of catheter ablation for atrial fibrillation among patients with moderate and advanced chronic kidney diseases: 2005 …
N Prasitlumkum, R Chokesuwattanaskul… - Journal of …, 2022 - Wiley Online Library
Introduction Real‐world data on atrial fibrillation (AF) ablation among moderate and
advanced chronic kidney disease (CKD) patients have so far remained scarce, especially in …
advanced chronic kidney disease (CKD) patients have so far remained scarce, especially in …
Показатели безопасности ривароксабана по сравнению с варфарином у пациентов с фибрилляцией предсердий и хронической болезнью почек поздних …
МИ Чашкина, ДА Андреев, НЛ Козловская… - Кардиология, 2020 - lib.ossn.ru
Аннотация Цель Оценка параметров безопасности применения ривароксабана у
пациентов с хронической болезнью почек (ХБП) 4‑й стадии или транзиторным …
пациентов с хронической болезнью почек (ХБП) 4‑й стадии или транзиторным …